Product Images Levetiracetam

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 11 images provide visual information about the product associated with Levetiracetam NDC 71093-123 by Aci Healthcare Usa, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

1000-mg - 1000 mg

250-mg - 250 mg

500-mg - 500 mg

Each tablet in this medication contains 500 mg of Levetiracetam USP. The dosage recommendations can be found in the package insert. The medication is in tablet form and comes in a bottle containing 120 tablets. It is important to keep this and all medications out of reach of children. The manufacturer of this medication is O VARNISH ZONE.*

750-mg - 750 mg

fig-1 - fig 1

This text provides information on the percentage of patients in different treatment groups and their corresponding dosages. The treatment groups include a placebo group (N=95), a levetiracetam 1000 mg/day group (N=97), and a levetiracetam 3000 mg/day group (N=101). However, without further context or additional information, it is not possible to determine the specific purpose or findings of this data.*

fig-2 - fig 2

This is a comparison of the percentage of patients in three different groups: placebo, levetiracetam 1000 mg/day, and levetiracetam 2000 mg/day. The number of patients in each group is provided in parentheses.*

fig-3 - fig 3

fig-4 - fig 4

This text provides the percentage of patients in a study who were given a placebo (n=97) and the percentage of patients who were given levetiracetam (n=101).*

fig-5 - fig 5

This is a comparison of the percentage of patients who received a placebo (19.6%) versus levetiracetam (43.1%). The study included a total of 51 patients in the placebo group and 58 patients in the levetiracetam group.*

fig-6 - fig 6

This text provides data on the percentage of patients in a study who were given a placebo (N=84) and levetiracetam (N=79). The percentages of patients for each group are 45.2% for placebo and 72.2% for levetiracetam.*

levestructure - levestructure

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.